AVEO Pharmaceuticals (NASDAQ:AVEO) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of AVEO Pharmaceuticals (NASDAQ:AVEO) in a report released on Tuesday, AnalystRatings.com reports. HC Wainwright currently has a $1.75 price target on the biopharmaceutical company’s stock.

Separately, Piper Jaffray Companies raised their price objective on shares of AVEO Pharmaceuticals from $3.00 to $4.00 and gave the stock an overweight rating in a research report on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. AVEO Pharmaceuticals currently has an average rating of Hold and an average target price of $2.25.

Shares of AVEO Pharmaceuticals stock opened at $0.84 on Tuesday. AVEO Pharmaceuticals has a 1 year low of $0.49 and a 1 year high of $3.06. The company has a debt-to-equity ratio of 6.84, a quick ratio of 2.21 and a current ratio of 2.21. The company has a market capitalization of $134.25 million, a P/E ratio of -4.40 and a beta of 0.71. The company’s fifty day moving average is $0.80 and its two-hundred day moving average is $0.78.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.04. AVEO Pharmaceuticals had a negative net margin of 46.69% and a negative return on equity of 50.69%. The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.78 million.

Several hedge funds have recently added to or reduced their stakes in AVEO. NEA Management Company LLC lifted its stake in shares of AVEO Pharmaceuticals by 20.8% in the 2nd quarter. NEA Management Company LLC now owns 25,243,865 shares of the biopharmaceutical company’s stock worth $16,913,000 after acquiring an additional 4,347,827 shares during the period. Vanguard Group Inc. lifted its stake in shares of AVEO Pharmaceuticals by 26.7% in the second quarter. Vanguard Group Inc. now owns 7,670,096 shares of the biopharmaceutical company’s stock valued at $5,164,000 after purchasing an additional 1,614,802 shares during the period. Paloma Partners Management Co acquired a new stake in shares of AVEO Pharmaceuticals in the second quarter valued at about $321,000. OZ Management LP acquired a new stake in shares of AVEO Pharmaceuticals in the second quarter valued at about $244,000. Finally, Morgan Stanley lifted its stake in shares of AVEO Pharmaceuticals by 265.4% in the second quarter. Morgan Stanley now owns 399,742 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 290,354 shares during the period. Institutional investors own 29.55% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Article: What Are Cryptocurrencies?

Analyst Recommendations for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.